Abstract 122P
Background
Cribriform (cbf) morphology has been shown in carcinomas from various organs, including prostate and breast, to be associated with worse patient outcomes and unique molecular features. We sought to examine the multimodal data from the landmark Cancer Genome Atlas (TCGA) study to clarify molecular and prognostic factors associated with cbf morphology in colorectal adenocarcinomas.
Methods
We retrospectively analyzed the available TCGA CRC cohort (n=594). Clinicopathological, digital slides, and molecular data were extracted. Cases with insufficient clinical data, no diagnostic slides, or poor slide quality were excluded. TCGA coded data, pathology reports, and digital diagnostic slides were reassessed by one gastrointestinal pathologist and a resident. Cbf morphology was graded using five categories based on prostate cribriform studies: (0) no-cribriform, (1) loose cribriform, (2) small cribriforming glands, (3) diffuse large cribriform, and (4) intraductal carcinoma of the prostate-like. Cases were grouped into cbf 'low' (0-1) and cbf 'high' (2-4) groups, which were correlated with clinicopathological, histological and molecular features. Immune infiltration was characterized by cell type fraction. An adjusted α = 0.05 for statistical significance was used for all tests.
Results
573 CRC cases were included. Cbf 'high' CRCs (159/573) were associated with more left-sided tumors (p=0.049), metastatic diseases (p=0.0001), less MSI-H (p=0.003), and different aneuploidy and fraction genome altered (p=0.003-0.008). Cbf 'high' vs 'low' tumors did not show a significant difference in grading distribution. T and N staging were not associated with cbf morphology. By cell fraction, cbf ‘high’ CRCs showed an immune infiltrate with increased regulatory T cells (p<0.0001) but decreased memory B cells (p=0.046), M2 macrophages (p<0.0001), neutrophils (p=0.018), resting dendritic cells (p=0.046), compared with cbf ‘low’ CRCs. Cbf 'high' tumor morphology was associated with worse overall survival outcomes by log-rank testing (p=0.037).
Conclusions
Cribriform morphology in colorectal adenocarcinoma TCGA cases was associated with poorer outcomes and distinct transcriptomic immune profiling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q-H. Trinh.
Funding
Fonds de recherche Santé Québec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract